Mostrar el registro sencillo del ítem
Evaluation of the performance of 18F-fluorothymidine positron emission tomography/computed tomography (18F-FLT-PET/CT) in metastatic brain lesions
dc.creator | Nikaki A., Papadopoulos V., Valotassiou V., Efthymiadou R., Angelidis G., Tsougos I., Prassopoulos V., Georgoulias P. | en |
dc.date.accessioned | 2023-01-31T09:40:12Z | |
dc.date.available | 2023-01-31T09:40:12Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.3390/diagnostics9010017 | |
dc.identifier.issn | 20754418 | |
dc.identifier.uri | http://hdl.handle.net/11615/77180 | |
dc.description.abstract | 18F-fluorothymidine (18F-FLT) is a radiolabeled thymidine analog that has been reported to help monitor tumor proliferation and has been studied in primary brain tumors; however, knowledge about 18F-FLT positron emission tomography/computed tomography (PET/CT) in metastatic brain lesions is limited. The purpose of this study is to evaluate the performance of 18F-FLT-PET/CT in metastatic brain lesions. A total of 20 PET/CT examinations (33 lesions) were included in the study. Semiquantitative analysis was performed: standard uptake value (SUV) with the utilization of SUVmax, tumor-to-background ratio (T/B), SUVpeak, SUV1cm3, SUV0.5cm3, SUV50%, SUV75%, PV50% (volume × SUV50%), and PV75% (volume × SUV75%) were calculated. Sensitivity, specificity, and accuracy for each parameter were calculated. Optimal cutoff values for each parameter were obtained. Using a receiver operating characteristic (ROC) curve analysis, the optimal cutoff values of SUVmax, T/B, and SUVpeak for discriminating active from non-active lesions were found to be 0.615, 4.21, and 0.425, respectively. In an ROC curve analysis, the area under the curve (AUC) is higher for SUVmax (p-value 0.017) compared to the rest of the parameters, while using optimal cutoff T/B shows the highest sensitivity and accuracy. PVs (proliferation × volumes) did not show any significance in discriminating positive from negative lesions. 18F-FLT-PET/CT can detect active metastatic brain lesions and may be used as a complementary tool. Further investigation should be performed. © 2019 by the authors. | en |
dc.language.iso | en | en |
dc.source | Diagnostics | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066419843&doi=10.3390%2fdiagnostics9010017&partnerID=40&md5=ef2edee5af60972db26b7e284116f1e8 | |
dc.subject | 3' fluorothymidine f 18 | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | area under the curve | en |
dc.subject | Article | en |
dc.subject | brain damage | en |
dc.subject | brain metastasis | en |
dc.subject | cell proliferation | en |
dc.subject | clinical article | en |
dc.subject | clinical assessment | en |
dc.subject | clinical evaluation | en |
dc.subject | controlled study | en |
dc.subject | diagnostic accuracy | en |
dc.subject | diagnostic test accuracy study | en |
dc.subject | female | en |
dc.subject | hemisphere | en |
dc.subject | human | en |
dc.subject | male | en |
dc.subject | maximum standardized uptake value | en |
dc.subject | peak standardized uptake value | en |
dc.subject | positron emission tomography-computed tomography | en |
dc.subject | quantitative analysis | en |
dc.subject | receiver operating characteristic | en |
dc.subject | retrospective study | en |
dc.subject | sensitivity and specificity | en |
dc.subject | standardized uptake value | en |
dc.subject | tumor volume | en |
dc.subject | very elderly | en |
dc.subject | MDPI AG | en |
dc.title | Evaluation of the performance of 18F-fluorothymidine positron emission tomography/computed tomography (18F-FLT-PET/CT) in metastatic brain lesions | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |